CSTL — Castle Biosciences, Inc.

Summary of Castle Biosciences Q4 and Full Year 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $87.0 million
• Full Year 2025 Revenue: $344.2 million, exceeding guidance.
• Test Report Volume: 105,053 reports for the year, a 37% increase year-over-year.
• Adjusted EBITDA: $44 million for the full year, down from $75 million in 2024.
• Net Loss: $24.2 million for the year, compared to net income of $18.2 million in 2024.
• Diluted Loss per Share: $0.83 for the year, compared to earnings of $0.62 in 2024.
• Gross Margin: 69.2% for the full year, down from 78.5% in 2024, affected by the loss of revenue from DecisionDx-SCC and amortization adjustments.

2. Strategic Updates and Business Highlights

• Core Revenue Drivers: Continued strong performance from DecisionDx-Melanoma (39,083 test reports, 9% growth) and TissueCypher (39,014 test reports, 86% growth).
• Acquisitions and Collaborations: Completed acquisition of Previse and entered a collaboration with SciBase.
• New Product Launch: Launched AdvanceAD-Tx test for atopic dermatitis, with initial positive uptake from dermatology accounts.
• Clinical Evidence: DecisionDx-Melanoma surpassed 230,000 test orders since launch, supported by 58 peer-reviewed publications.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $340 million to $350 million, reflecting mid- to high-teens growth excluding certain revenues.
• Volume Growth Expectations: Anticipated mid- to high single-digit growth for DecisionDx-Melanoma and continued strong growth for TissueCypher.
• AdvanceAD-Tx Contribution: Expected to be immaterial in 2026, with material contributions anticipated in 2027 or 2028.

4. Bad News, Challenges, or Points of Concern

• Declining Profitability: Significant net loss and decreased adjusted EBITDA compared to the previous year raise concerns about profitability.
• Gross Margin Pressure: Decreased gross margin due to revenue loss from DecisionDx-SCC and amortization adjustments.
• Regulatory Risks: Uncertainty regarding the FDA submission timeline for DecisionDx-Melanoma and potential impacts on reimbursement discussions.
• Market Competition: Ongoing competitive pressures in the diagnostics market, particularly for melanoma and gastrointestinal tests.

5. Notable Q&A Insights

• NCCN Guidelines: Discussion on the NCCN update revealed that DecisionDx-Melanoma was not recommended, despite substantial supporting evidence, indicating a potential challenge in gaining guideline inclusion.
• Sales Strategy for AdvanceAD-Tx: High clinician awareness and initial adoption suggest strong market interest, with plans to expand access based on internal metrics.
• TissueCypher Growth: Continued focus on expanding the sales team and penetrating larger group practices, with expectations for ongoing volume growth.
• Potential for SCC Test Reimbursement: If a positive draft LCD for DecisionDx-SCC is published, the company may need to adjust its sales strategy to accommodate three tests, indicating a proactive approach to potential growth opportunities.

Overall, Castle Biosciences demonstrated strong revenue growth and strategic advancements in 2025, despite facing challenges related to profitability and regulatory uncertainties. The company remains focused on expanding its market presence and enhancing its product offerings.